Ad
related to: novartis ixiaro news
Search results
Results From The WOW.Com Content Network
On Thursday, Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular ...
Valneva along with Dynavax Technologies [11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, [12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.
AOL latest headlines, entertainment, sports, articles for business, health and world news.
(Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar ...
It uses the same manufacturing technology as Valneva's Ixiaro vaccine for Japanese encephalitis. [1] History. Clinical trials. ...
FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...
Deferasirox, sold under the brand name Exjade among others, is an oral iron chelator.Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%. The Swiss group will ...